培美曲塞联合奥沙利铂、顺铂治疗晚期肺腺癌的临床研究被引量：3

导出

摘要肺癌在全球范围内发病率及死亡率均高居恶性肿瘤首位，并呈逐渐增加的趋势［1］。肺癌的75％～80％是非小细胞肺癌，其中50％以上是肺腺癌。大多数患者在就诊时已为晚期（ⅢB期、Ⅳ期）［2］，目前晚期肺癌患者主要的化疗方案是含铂两药联合，本研究应用培美曲塞分别联合奥沙利铂、顺铂治疗晚期肺腺癌，观察其疗效、6个月及12个月生存率、Karnof-sky功能状态（KPS）评分及不良反应。

作者周莉朱小鹏

机构地区湖北省黄石市中心医院腹盆腔肿瘤内科

出处《国际肿瘤学杂志》 CAS 2014年第9期715-717,共3页 Journal of International Oncology

关键词晚期肺腺癌奥沙利铂培美曲塞临床研究治疗顺铂非小细胞肺癌肺癌患者

分类号 R734.2 [医药卫生—肿瘤]

作者简介通信作者：朱小鹏，E-mail：35161280@qq．com

引文网络
相关文献

参考文献9

1朱小鹏,唐昃.NP方案联合同步放疗治疗局部晚期非小细胞肺癌的疗效观察[J].临床肺科杂志,2013,18(1):164-165. 被引量：8
2NSCLC MetaAnalyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced nonsmallcell lung cancer: asystematic review and metaanalysis of individual patient data from 16 randomized controlled trials[J].J Clin Oncol.2008, 26(28):4617-4625.
3AlSaleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced nonsmallcell lung cancer: metaanalysis of randomized controlled trials, with histology subgroup analysis[J]. Curr Oncol, 2012, 19(1): e9-e15.
4Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non smallcell lung cancer: special focus on pharmacology and mechanism of action[J].Curr Drug Targets.2010, 11(1):37-47.
5王治宽,胡毅,赵宏,付晨.晚期肺腺癌胸苷酸合成酶和培美曲塞疗效分析[J].南方医科大学学报,2010,30(5):978-980. 被引量：19
6Mir O, BoudouRouquette P, Giroux J, et al. Pemetrexed, oxaliplatin and bevacizumab as firstline treatment in patients with stage Ⅳ nonsmall cell lung cancer[J].Lung Cancer.2012, 77(1):104-109.
7Misset JL, Gamelin E, Campone M, et al. Phase Ⅰ and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors[J].Ann Oncol.2004, 15(7):1123-1129.
8田述梅.培美曲塞联合奥沙利铂或顺铂一线治疗晚期肺腺癌的临床研究[J].现代医药卫生,2012,28(17):2570-2572. 被引量：4
9Shi SB, Hu RH, Qi JL, et al. Treatment of stage Ⅲb/Ⅳ nonsmall cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as secondline treatment[J].Med Oncol.2013, 30(2):550-.

二级参考文献27

1SehillerJH, HarringtonD, BelaniCP, etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med, 2002, 346:92-8.
2Simon GR, Sharma S, Cantor A, et al. RECC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J]. Chest, 2005, 127(3): 978-83.
3RoseU R, Cecere F, Santarpia M, et al. Predicting the outcome of chemotherapy for lung cancer[J]. Curr Opin Phamacol, 2006, 6(4): 323-31.
4Calvert H. An overview of folate metabolism: features relevant to the action and toxicities ofantifolate anticancer agents [J]. Semin Oncol, 1999, 26( 2 Suppl 6): 3-10.
5Adjei AA. Pharmacology and mechanism of action ofpemetrexed [J]. Clin Lung Cancer, 2004, 5( Suppl 2): S51-5.
6Joerger M, Omlin A, Cemy T, et al. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action [J]. Curr Drug Targets, 2010, 11 (1):37-47.
7Ohrling K, Edler D, Hallstrom M, et al. Detection of thymidylate synthase expression in lymph node metastases of eoloreetal cancer can improve the prognostic information [J]. J Clin Oncol, 2005, 23 (24): 5628-34.
8Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in coloreetal eeneer patients receiving 5-fluorouracil-based chemotherapy[J]. Clin Ceneer Re, s, 2004, 10(17): 5880-8.
9Kommann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil [ J ]. Clin Cancer Res, 2003, 9( 11 ): 4116-24.
10Sakamoto J, Hamashima H, Suzuki H, et al. Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial[J]. Oncol Rep, 2003, 10(5): 1081-90.